申请人:MedImmune Oncology, Inc.
公开号:US06258952B1
公开(公告)日:2001-07-10
The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group Poverscore (1)}(#2) and having a triclinic cell with dimensions of about a=7.699 Å, b=9.606 Å and c=13.012 Å is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline, is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form.
本发明提供了2,4-二氨基-5-甲基-6-[(3,4,5-三甲氧基苯胺基)甲基]喹唑啉或三甲氧喹唑啉的热稳定形式。其中一种晶体形式为2,4-二氨基-5-甲基-6-[(3,4,5-三甲氧基苯胺基)甲基]喹唑啉单水合物或三甲氧喹唑啉单水合物,属于空间群Poverscore (1)}(#2),其三斜晶胞的尺寸约为a=7.699 Å,b=9.606 Å和c=13.012 Å。本发明还公开了一种新型席夫碱化合物,即2,4-二氨基-5-甲基-6-[(3,4,5-三甲氧基苯基亚甲基)亚甲基]喹唑啉。本发明还提供了制备稳定的三甲氧喹唑啉游离基化合物的新方法,包括制备晶体三甲氧喹唑啉单水合物。晶体单水合物形式相较于无水形式具有更高的稳定性。